Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases

The prevalence of type 2 diabetes mellitus (T2DM) is rising in the general population. This increase leads to higher cardiovascular risk, with diseases being main cause death diabetic patients. New therapeutic weapons for are now available. Sodium-glucose cotransporter (SGLT2) inhibitors novel drugs that widely used due their strong benefit preventing hospitalization decompensated heart failure and renal protection, limiting deterioration glomerular filtration rate, independently presence mellitus. These have also shown prevention atherosclerotic events mortality patients established disease. On other hand, T2DM usually present a high burden associated comorbidities. Some these entities arterial hypertension, dyslipidemia, hyperuricemia, obesity, non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), vascular aging, respiratory diseases, or osteoporosis fractures. Healthcare professionals should treat from an integral point view, not manage each pathology separately. Therefore, as potential mechanisms SGLT2 metabolic been fully reviewed, we conducted this review know current evidence use effect on diseases.